RESEARCH DIGEST / MECHANISM · THE STUDY RECORD
NAD+ Research: How It Works, Why It Falls With Age, and What the Studies Found
The redox role, the enzymes that burn through the pool, the age-related decline, and the preclinical findings — pinned to source, sorted by how much weight each one can bear.
In plain English
NAD+ does two jobs in a cell. First, it is an energy go-between: it carries electrons through the chemistry that turns food into ATP (the cell's usable energy), flipping between a "loaded" form (NADH) and an "empty" form (NAD+) over and over (this electron-carrying chemistry is called redox). Second, it is a consumable — certain repair-and-maintenance enzymes use it up as they work, so the cell has to keep making more. As you age, the supply drops and one enzyme that destroys NAD+ (CD38) ramps up, leaving less to go around. That decline is the biology behind the whole "boost your NAD+" idea. Below is the mechanism and the study record, kept honest about which findings come from humans and which from mice.
The redox engine and the enzymes that consume it
NAD+ is the cell's central redox carrier. It shuttles electrons through glycolysis, the TCA cycle and mitochondrial oxidative phosphorylation — cycling NAD+ ⇄ NADH — to drive ATP synthesis [5]. That redox role is ancient and non-negotiable; without it, energy metabolism stops. Layered on top is a second economy: NAD+ is consumed (not just recycled) by three enzyme families. Sirtuins (SIRT1–SIRT7, NAD+-dependent deacylases) regulate metabolism, stress resistance and DNA repair. PARP1 (poly(ADP-ribose) polymerase 1) consumes large amounts of NAD+ to repair DNA damage. And CD38 / CD157 are NAD-consuming ectoenzymes that rise with age and inflammation [5]. Because all three draw on the same NAD+ pool, they compete — and a foundational review framed restoring NAD+ as a candidate strategy against age-related disease precisely because that pool shrinks with age [5].
Why NAD+ falls with age — the CD38 story
The clearest mechanistic account of age-related NAD+ decline points at CD38. In mice, CD38 is the principal NAD+-consuming enzyme, and its activity rises with age, driving the fall in tissue NAD+ [2]. CD38-knockout mice are protected: deleting CD38 preserves NAD+ levels and SIRT3 activity and improves mitochondrial function and metabolic health with age [2]. This is the rationale behind precursor supplementation — if an aging cell is losing NAD+ partly because CD38 is eating it, topping up the supply with NMN or NR is one way to defend the pool. Worth flagging plainly: this is mouse work. It explains why you might boost NAD+; it does not by itself prove that doing so extends human healthspan.
How precursors rebuild the pool
The body makes NAD+ by three routes: de novo from the amino acid tryptophan, the Preiss-Handler pathway from nicotinic acid (niacin), and — dominant in mammals — the salvage pathway, which recycles nicotinamide back into NAD+ via the rate-limiting enzyme NAMPT [5]. Oral precursors plug into this machinery. NR is converted to NMN by NRK kinases and then to NAD+, taking a route independent of Preiss-Handler [5]. The plumbing is more tangled than it looks: isotope tracing in mice showed circulating host nicotinamide feeds the gut microbiome, which converts it to nicotinic acid used for host NAD+ synthesis, and that oral NR reaches host NAD+ partly via microbial conversion [12]. NAMPT also follows a circadian rhythm and is induced by exercise [5] — context for the timing questions below.
What the preclinical record shows beyond metabolism
Outside core metabolism, animal studies have probed NAD+ in specific tissues — and these are explicitly preclinical. In mice, photoreceptor-specific deletion of the NAD+ enzyme Nampt caused retinal degeneration that NMN could rescue, identifying NAD+ biosynthesis as essential for vision and a shared target across blinding diseases [11]. In a noise-exposure model, NR given before exposure preserved cochlear hair-cell ribbon synapses and aided hearing recovery [14]. And a review of human and laboratory evidence reports that nicotinamide replenishes the cellular NAD+ pool and, applied topically, reduced progression of skin aging and hyperpigmentation in clinical trials while being well tolerated [13]. These widen the mechanistic map; they are mostly rodent or topical findings, and the cautions on the safety page about extrapolating from mice to people apply throughout.
Does NAD cause weight gain?
The dealt studies do not show NAD+ precursors causing weight gain. Human trials report no body-composition change with NMN — for example 250 mg/day for 10 weeks improved muscle insulin sensitivity but did not alter body composition or HbA1c [1]. Body weight was not an outcome these trials moved in either direction.
Does NAD help with weight loss?
Some trials report improved muscle insulin sensitivity at NMN doses around 250 mg/day [1], but the dealt studies do not establish weight loss as an outcome and report no body-composition change. NAD+ precursors are not demonstrated weight-loss agents in this evidence base.
Does NAD make you look younger?
No trial in the dealt evidence demonstrates a cosmetic "younger" effect. Mechanistic reviews link declining tissue NAD+ to aging biology — sirtuins, PARPs, CD38 [5] — and topical nicotinamide has reduced skin-aging signs in clinical trials [13], but systemic human anti-aging outcomes remain preliminary [15].
Does NAD help with fertility?
Fertility is outside the dealt evidence base. Reviews caution that most of the strongest NAD+ data are mechanistic or rodent, and that human clinical endpoints remain unproven [15]. The studies summarized here did not measure fertility outcomes.
What is the best time to take NAD, morning or night?
No trial establishes a best time of day to take a precursor. NAMPT, the salvage-pathway enzyme, and NAD+ itself follow a circadian rhythm [5], which is sometimes cited in timing discussions, but the dealt randomized trials dosed on fixed schedules without comparing morning versus night, so the evidence does not pick a winner.